CSIMarket
 
Mink Therapeutics Inc   (INKT)
Other Ticker:  
 
 
Price: $0.8945 $0.00 0.506%
Day's High: $0.9137 Week Perf: -5.8 %
Day's Low: $ 0.81 30 Day Perf: -10.51 %
Volume (M): 38 52 Wk High: $ 3.34
Volume (M$): $ 34 52 Wk Avg: $1.45
Open: $0.89 52 Wk Low: $0.75



 Market Capitalization (Millions $) 31
 Shares Outstanding (Millions) 35
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -25
 Cash Flow (TTM) (Millions $) -32
 Capital Exp. (TTM) (Millions $) 0

Mink Therapeutics Inc
Mink Therapeutics Inc is a biotechnology company that focuses on developing targeted mRNA therapies for treating various diseases. The company's approach involves using modified mRNA molecules to produce therapeutic proteins within the patient's cells, aiming to address the underlying causes of diseases at a genetic level. Mink Therapeutics aims to leverage mRNA technology to create personalized treatments for a range of conditions, including rare genetic disorders, cancer, and infectious diseases. The company utilizes its proprietary platform and expertise in mRNA therapeutics to advance its drug development pipeline and potentially revolutionize the field of gene therapy.


   Company Address: 149 Fifth Avenue New York 10010 NY
   Company Phone Number: 994-8250   Stock Exchange / Ticker: NASDAQ INKT
   INKT is expected to report next financial results on March 23, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

AgenT-797: A Promising Breakthrough in Overcoming Immune Checkpoint Inhibitor Resistance in Refractory Gastric Cancer

Published Wed, Feb 14 2024 1:00 PM UTC

MiNK Therapeutics, a clinical-stage biopharmaceutical company, recently announced the initiation of a Phase 2 investigator sponsored study for agenT-797 in second line gastroesophageal cancer. Led by Dr. Yelena Janjigian at the Memorial Sloan Kettering Cancer Center, this study aims to build upon the remarkable findings from MiNK's previous clinical trial, demonstrating the ...

Clinical Study

AgenT-797: A Beacon of Hope in the Battle Against Severe Acute Respiratory Distress Syndrome

Published Tue, Feb 6 2024 1:01 PM UTC

Severe acute respiratory distress syndrome (ARDS) is a life-threatening condition that presents various challenges for medical professionals. The development of effective therapies targeted towards improving survival rates in patients with ARDS is an urgent need. In this regard, a breakthrough study published in Nature Communications reports promising results from the use of...

Clinical Study

MiNKs AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer

Published Tue, Jan 30 2024 1:01 PM UTC

Abstract:This article discusses the groundbreaking findings of a case report published in Oncogene by MiNK Therapeutics, Inc. The study highlights the potential of MiNK's allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapy, agenT-797, to overcome resistance to immune checkpoint inhibitors (ICIs) in treating advanced solid tumors, specifically gastric ca...

Partnership

Joint Venture Between ImmunoScape and MiNK Therapeutics: A Quantum Leap in Cancer Therapeutic Development

Published Wed, Dec 20 2023 12:30 PM UTC


Biotechnology company ImmunoScape and clinical-stage biopharmaceutical firm MiNK Therapeutics, Inc. (Nasdaq: INKT) have made a groundbreaking announcement; Both entities have teamed up to expedite the discovery and development of next-generation T cell receptor (TCR)-based treatments. As internationally recognized enterprises, they unite with a shared vision of combatin...

Mink Therapeutics Inc

INKT Suffers Operating Shortfall in Third Quarter 2023, but Optimizes Costs for Improved Results

he Biotechnology & Pharmaceuticals industry has witnessed the financial results of major players as well as smaller corporations. In the third quarter of 2023, INKT reported an operating shortfall of $-5.223561 million, highlighting a significant decline in day-to-day operations compared to the same period last year. On the other hand, Mink Therapeutics Inc. has managed to optimize costs, leading to a decrease in operating losses during this earnings season.
INKT's Operating Shortfall and Revenue Streams:
INKT, which primarily operates in the development cycle, reported an operating shortfall of $-5.223561 million for the third quarter of 2023. This figure indicates a substantial decrease compared to the same quarter in 2022 when the operating shortfall was recorded at $-6.332 million. Despite the shortfall, it is important to note that INKT has succeeded in optimizing its costs, resulting in a lower deficit compared to the previous year.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com